The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000542392
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
25/03/2026
Date registered
Help: Date registered
30/04/2026
Date last updated
Help: Date last updated
30/04/2026
Date data sharing statement initially provided
Help: Data sharing statement date
30/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
MOM NOSE Best: Mothers Own Milk Intranasally or Standard Care in Preterm Babies with Intraventricular Haemorrhage
Scientific title
Mothers Own Milk Intranasally or Standard Care in Preterm Babies with Intraventricular Haemorrhage
Additional trial identifiers [1] 316630 0
None
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Germinal Matrix-Intraventricular Haemorrhage 340836 0
Post haemorrhagic ventricular dilatation 340837 0
Condition category
Condition code
Reproductive Health and Childbirth 336998 336998 0 0
Complications of newborn
Neurological 337566 337566 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Intranasal fresh mothers own milk (target 1.6ml/day in divided doses) for 28 days commenced as soon as possible after Germinal Matrix Haemorrhage-Intraventricular Haemorrhage (GMH-IVH) detection, in addition to standard care. 0.8ml of fresh mothers own milk will be administered twice per day clustered around routine infant nursing cares and timed with availability of fresh mothers own milk. During a care cluster 0.4ml fresh mothers own milk (0.2ml per nostril, delivered via droplets from a syringe) will be instilled immediately prior to and repeated immediately after a set of nursing cares . To ensure intranasal administration is tolerated, dosage will begin at 0.2mL (0.1mL per nostril) and increased over 24h. Nasal suction is to be avoided for an hour following mothers own milk intranasal administration. In case of nasal endotracheal tube placement, the full dose of mothers own milk will be administered into the contralateral nostril. All administration will occur within the neonatal unit by nursery staff. Doses will be prescribed and monitored using hospital electronic medical records.

Breast milk collection: Lactation and expressing support and equipment will be offered to mothers as is standard care in the nurseries. Intranasal mothers own milk administration will need to occur within 3 hours of expression without prior refrigeration. To reduce the burden of this on families, fresh mothers own milk administration will be clustered so that only two fresh samples are needed per day (reduced to one cluster if necessary).
Intervention code [1] 333310 0
Treatment: Other
Description of the comparator or control
Standard care (supportive care in the neonatal nursery appropriate to gestational age, eg serial cranial ultrasounds to monitor any progression).
Control group
Active

Outcomes
Primary outcome [1] 344526 0
Post Haemorrhagic Ventricular Dilatation
Timepoint [1] 344526 0
At any time during neonatal admission. Serial cranial ultrasound surveillance will occur on days of life 1-3, 4-7, 10-14, 4 weeks, 6 weeks and term equivalent age or pre discharge, with additional scans once to twice per week in case of PHVD
Secondary outcome [1] 458184 0
Post Haemorrhagic Ventricular Dilatation severity
Timepoint [1] 458184 0
At any time during neonatal admission. Serial cranial ultrasound surveillance will occur on days of life 1-3, 4-7, 10-14, 4 weeks, 6 weeks and term equivalent age or pre discharge, with additional scans once to twice per week in case of PHVD
Secondary outcome [2] 458185 0
Maximal Ventricular Index
Timepoint [2] 458185 0
At any time during neonatal admission. Serial cranial ultrasound surveillance will occur on days of life 1-3, 4-7, 10-14, 4 weeks, 6 weeks and term equivalent age or pre discharge with additional scans once to twice per week in case of PHVD
Secondary outcome [3] 458186 0
Duration of Post Haemorrhagic Ventricular Dilatation
Timepoint [3] 458186 0
At any time during neonatal admission. Serial cranial ultrasound surveillance will occur on days of life 1-3, 4-7, 10-14, 4 weeks, 6 weeks and term equivalent age or pre discharge , with additional scans once to twice per week in case of PHVD
Secondary outcome [4] 458187 0
Progression in intraventricular haemorrhage
Timepoint [4] 458187 0
At any time during neonatal admission. Serial cranial ultrasound surveillance will occur on days of life 1-3, 4-7, 10-14, 4 weeks, 6 weeks and term equivalent age or pre discharge , with additional scans once to twice per week in case of PHVD
Secondary outcome [5] 458440 0
Lumbar puncture
Timepoint [5] 458440 0
Any therapeutic lumbar puncture procedure performed to reduce PHVD/hydrocephalus until 1 year corrected age
Secondary outcome [6] 458441 0
Head circumference
Timepoint [6] 458441 0
Weekly until hospital discharge
Secondary outcome [7] 458442 0
Seizures during neonatal admission (clinical and/or electrographic where Amplitude-integrated electroencephalogram (aEEG) performed)
Timepoint [7] 458442 0
Occurring at any time during neonatal admission.
Secondary outcome [8] 458443 0
All-cause mortality
Timepoint [8] 458443 0
During primary hospital admission or at time of death within first 3 years corrected age
Secondary outcome [9] 458444 0
Bronchopulmonary dysplasia
Timepoint [9] 458444 0
At 36 weeks corrected gestational age
Secondary outcome [10] 458446 0
Length of stay (days)
Timepoint [10] 458446 0
At time of neonatal discharge
Secondary outcome [11] 458449 0
Volume of intranasal MOM treatments given
Timepoint [11] 458449 0
Daily during 28 day treatment period
Secondary outcome [12] 458450 0
Routine nasal bacterial colonisation screening results
Timepoint [12] 458450 0
Weekly while in NICU as per standard care
Secondary outcome [13] 458452 0
Routine haematology
Timepoint [13] 458452 0
Any routine daily haematology collected during first 6 weeks of life
Secondary outcome [14] 458454 0
Fever within 2 hours of intranasal MOM administration
Timepoint [14] 458454 0
Within 2 hours post each administration during the 28 day intervention period
Secondary outcome [15] 458455 0
General movements
Timepoint [15] 458455 0
3 months corrected age
Secondary outcome [16] 458456 0
Neurodevelopment at 2-3 years of age
Timepoint [16] 458456 0
A single assessment at 2-3 years corrected age
Secondary outcome [17] 460275 0
Necrotising Enterocolitis greater or equal to Bells stage II
Timepoint [17] 460275 0
At death or at primary hospital discharge
Secondary outcome [18] 460277 0
Retinopathy of Prematurity greater or equal to stage 2
Timepoint [18] 460277 0
At death or at primary hospital discharge
Secondary outcome [19] 460278 0
Late onset sepsis
Timepoint [19] 460278 0
At death of at to primary hospital discharge
Secondary outcome [20] 460279 0
Number of intranasal MOM treatments missed
Timepoint [20] 460279 0
Daily during the 28 day treatment window
Secondary outcome [21] 460280 0
Maximal Anterior Horn Width
Timepoint [21] 460280 0
Serial cranial ultrasound surveillance occurring on days of life 1-3, 4-7, 10-14, 4 weeks, 6 weeks, term equivalent or pre discharge, with additional scans once to twice per week in case of PHVD
Secondary outcome [22] 460281 0
Maximal Thalamo-Occipital Distance
Timepoint [22] 460281 0
Serial cranial ultrasound surveillance occurring on days of life 1-3, 4-7, 10-14, 4 weeks, 6 weeks, term equivalent or pre discharge, with additional scans once to twice per week in case of PHVD
Secondary outcome [23] 460282 0
Periventricular haemorrhagic infarction
Timepoint [23] 460282 0
Serial cranial ultrasound surveillance occurring on days of life 1-3, 4-7, 10-14, 4 weeks, 6 weeks, term equivalent or pre discharge
Secondary outcome [24] 460283 0
Periventricular leucomalacia
Timepoint [24] 460283 0
Serial cranial ultrasound surveillance occurring on days of life 1-3, 4-7, 10-14, 4 weeks, 6 weeks, term equivalent or pre discharge
Secondary outcome [25] 460284 0
Porencephalic cyst
Timepoint [25] 460284 0
Serial cranial ultrasound surveillance occurring on days of life 1-3, 4-7, 10-14, 4 weeks, 6 weeks, term equivalent or pre discharge
Secondary outcome [26] 460285 0
Ventricular reservoir insertion
Timepoint [26] 460285 0
At point of reservoir insertion, monitored until 3 years corrected age
Secondary outcome [27] 460286 0
Ventriculoperitoneal shunt insertion
Timepoint [27] 460286 0
At time of ventriculoperitoneal shunt insertion, monitored till 3 years corrected age

Eligibility
Key inclusion criteria
Preterm infants (<37 weeks gestation at birth) with any grade Germinal-Matrix-Intraventricular Haemorrhage on cranial ultrasound in the first 10 days of life
Minimum age
No limit
Maximum age
37 Weeks
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Postnatal age greater than 10 days at time of enrolment, Congenital diagnosis associated with neurodevelopmental delay or impairment, Neonate with no reasonable likelihood of survival, Choanal atresia or anomalies that would not allow intranasal treatment, Parent with lactation contraindication(s) or parent who declines lactation initiation, Lactating parent unable to provide fresh breast milk: unable/unwilling to pump at study site or unable to have fresh mothers own milk delivered by designee at least once/day within 3 hours of pumping for 28 days

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Yes. Sealed opaque envelopes used
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
A computer-generated randomisation schedule using balanced variable block design with an allocation ratio of 1:1 will be generated by an independent statistician not involved with trial participants or data analysis. Stratification will be used for sex, gestational ages at birth (26+0 weeks) and GMH-IVH severity at enrolment (low grade I-II, and high grade III-PVHI). Infants from multiple births will be randomised to the same treatment group.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA

Funding & Sponsors
Funding source category [1] 321248 0
Self funded/Unfunded
Name [1] 321248 0
Country [1] 321248 0
Primary sponsor type
Government body
Name
Southern Adelaide Local Health Network
Address
Country
Australia
Secondary sponsor category [1] 323957 0
None
Name [1] 323957 0
Address [1] 323957 0
Country [1] 323957 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319774 0
Women's and Children's Health Network Human Research Ethics Committee
Ethics committee address [1] 319774 0
Ethics committee country [1] 319774 0
Australia
Date submitted for ethics approval [1] 319774 0
03/12/2025
Approval date [1] 319774 0
16/02/2026
Ethics approval number [1] 319774 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148358 0
Dr Kathryn Martinello
Address 148358 0
Flinders Medical Centre Level 4 Flinders Drive, Bedford Park, South Australia, 5042
Country 148358 0
Australia
Phone 148358 0
+61 08 82044595
Fax 148358 0
Email 148358 0
Contact person for public queries
Name 148359 0
Dr Tara Crawford
Address 148359 0
Flinders Medical Centre Level 4 Flinders Drive, Bedford Park, South Australia, 5042
Country 148359 0
Australia
Phone 148359 0
+61 08 82044595
Fax 148359 0
Email 148359 0
Contact person for scientific queries
Name 148360 0
Kathryn Martinello
Address 148360 0
Flinders Medical Centre Level 4 Flinders Drive, Bedford Park, South Australia, 5042
Country 148360 0
Australia
Phone 148360 0
+61 08 82044595
Fax 148360 0
Email 148360 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• De-identified individual participant data:
• Published results
• Primary outcome(s)
• Safety data
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
No end date
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: Email to primary investigator ([email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.